Evidence-Based Management of the Diabetes Epidemic 2019

Schedule

Start 13 November, 2019, 12 PM

End 4 55 PM

Location

360 James Street North

Hamilton

ON

No country specified

Liuna Station

Contact Info

Natalie Park, CHSE Coordinator

Phone: 905-525-9140 ext. 20763

E-Mail: parkna@mcmaster.ca

No website provided


Download the brochure 

Sign up for email updates

💻 SOLD OUT! Sign up for the waiting list  

Download the 2019 presentations
*you will require the password given to access the presentations


TARGET AUDIENCE

Family Physicians, Specialists, Physician Assistants, Optometrists, Pharmacists, IMGs, Nurse Educators/Practitioners, Dietitians, and Residents.

LEARNING OBJECTIVES 

By attending this activity, participants will be able to: 

  • Describe the evidence for benefit for adjunctive therapy to insulin for type 1 diabetes and apply DKA risk mitigation strategies to SGLT2 inhibitor therapy in type 1 diabetes.

  • Understand when real-world evidence or evidence from randomized controlled trials should be used to evaluate research publications.

  • Tailor glucose-lowering drugs to patient’s unique profile with respect to diabetes status and review the evidence supporting therapeutic choices in diabetes management.

  • Utilize current evidence and approaches regarding dietary management of diabetes.

  • Explain the benefits of CGM in the management of pregnant patients with type 1 DM.

  • Discuss the use of sensor augmented pump therapy in patients with type 1 DM.

  • Recall the true burden of all types of hypoglycemia in patients with diabetes in Canada and the relevance of Real-World patient-reported data for this outcome.

  • Critically reflect on the need for a new definition of hypoglycemia that recognizes the patients’ reality in living with hypoglycemia.

 

PRESENTATION SPECIFIC LEARNING OBJECTIVES


Keynote Talk: Beyond Insulin Treatment for Glycemic Control of Type 1 Diabetes

John B. Buse, MD, PhD

Presentation Objectives 

By attending this activity, participants will be able to: 

1. Describe the evidence for benefit for adjunctive therapy to insulin for type 1 diabetes                                                   
2. Apply DKA risk mitigation strategies to SGLT2 inhibitor therapy in type 1 diabetes

 

Real World Evidence, RCTs & Big Data: What Should you Believe and When?

Hertzel Gerstein, MD, MSc, FRCPC

Presentation Objectives 

By attending this activity, participants will be able to: 

1. Rank different forms of evidence to determine the best evidence to determine the best evidence to answer questions regarding therapy and prognosis 

 

Clinical Cases 1: Tailoring the Glucose Lowering Drug to the Patient’s Needs

Zubin Punthakee, MD, MSc, FRCPC

Presentation Objectives 

By attending this activity, participants will be able to: 

1. Tailored glucose-lowering drugs to patient’s unique profile with respect to diabetes status

2. Review the evidence supporting therapeutic choices in diabetes management 

 

Hot Topics in Nutrition and Diabetes – A Case Based Approach

Yvonne Mullan, MSc, RD, CDE 

Presentation Objectives 

By attending this activity, participants will be able to: 

1. Identify concerns associated with popular fad diets

2. Utilize current evidence to Identify healthy meal patterns associated with improved diabetes outcomes and CVD risk

3. Identify reliable online nutrition resources for patients

 

Clinical Cases 2: Newer Approaches for Pregnancy and for Type 1 Diabetes

Meera Luthra, MD, FRCP(C)

Presentation Objectives 

By attending this activity, participants will be able to: 

1. Explain the benefits of CGM in the management of pregnant patients with type 1 DM                                       

2. Discuss the use of sensor augmented pump therapy in patients with type 1 DM

 

Hypoglycemia: Is it really a problem?

Stewart Harris, MD, MPH, FCFP &

Alexandria Ratzki-Leewing, MSc, PhD(c)

Presentation Objectives 

By attending this activity, participants will be able to: 

  1. Better describe the true burden of all types of hypoglycemia in patients with both T1DM/T2DM at a population level in Canada
  2. Determine the relevance and importance of Real-World patient-reported data to better appreciate the impact on at-risk patients experiencing hypoglycemia
  3. Discuss the need for a new definition of hypoglycemia that recognizes the patients’, reality in living with hypoglycemia